Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun 1;84(6):665.
doi: 10.1097/JCMA.0000000000000548.

Reply to "Was capsule penetration of locally advanced renal cell carcinoma associated with recurrence in patients undergoing curative surgery?"

Te-Wei Chang  1 , Wei-Ming Cheng  1   2 , Yu-Hua Fan  2   3 , Chih-Chieh Lin  2   3 , Tzu-Ping Lin  2   3 , Eric Yi-Hsiu Huang  2   3 , Hsiao-Jen Chung  2   3 , William J S Huang  2   3 , Shih-Han Weng  4
Affiliations
Comment

Reply to "Was capsule penetration of locally advanced renal cell carcinoma associated with recurrence in patients undergoing curative surgery?"

Te-Wei Chang et al. J Chin Med Assoc. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr. William J. S. Huang, an editorial board member at Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

Comment on

Similar articles

See all similar articles

References

    1. Chou FW, Chang WH, Wang PH. Was capsule penetration of locally advanced renal cell carcinoma associated with recurrence in patients undergoing curative surgery? J Chin Med Assoc. 2021; 84:664.
    1. Chang TW, Cheng WM, Fan YH, Lin CC, Lin TP, Eric Huang YH, et al. Predictive factors for disease recurrence in patients with locally advanced renal cell carcinoma treated with curative surgery. J Chin Med Assoc. 2021; 84:405–9.
    1. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016; 387:2008–16.
    1. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al.; S-TRAC Investigators. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016; 375:2246–54.

LinkOut - more resources